Type 2 diabetes care: the role of insulin-sensitizing agents and practical implications for cardiovascular disease prevention (Q43979001)

28 November 2017

1 reference

title

Type 2 diabetes care: the role of insulin-sensitizing agents and practical implications for cardiovascular disease prevention (English)

1 reference

28 November 2017

1 reference

cardiovascular disease

1 reference

R R Henry

1

1 reference

PubMed ID

9707264

28 November 2017

language of work or name

English

0 references

publication date

1 July 1998

1 reference

American Journal of Medicine

28 November 2017

1 reference

28 November 2017

105

1 reference

28 November 2017

20S-26S

1 reference

28 November 2017

1A

1 reference

Impaired glucose tolerance in the U.S. population.

28 November 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900207-1

Insulin resistance: syndrome or tendency?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900207-1

The insulin resistance syndrome revisited

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900207-1

The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900207-1

The effect of long-term intensified insulin treatment on the development of microvascular complications of diabetes mellitus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900207-1

Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900207-1

NIDDM and its metabolic control predict coronary heart disease in elderly subjects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900207-1

Ten-year cardiovascular mortality in relation to risk factors and abnormalities in lipoprotein composition in type 2 (non-insulin-dependent) diabetic and non-diabetic subjects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900207-1

Hyperglycemia and microvascular and macrovascular disease in diabetes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900207-1

Undiagnosed diabetes or impaired glucose tolerance and cardiovascular risk

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900207-1

Features of syndrome X in first-degree relatives of NIDDM patients.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900207-1

Nonketotic diabetes mellitus: insulin deficiency or insulin resistance?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900207-1

Banting lecture 1988. Role of insulin resistance in human disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900207-1

Insulin and atheroma. 20-yr perspective

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900207-1

Associations between insulin levels and cardiovascular disease are confounded by comorbidity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900207-1

Low insulin sensitivity is associated with clustering of cardiovascular disease risk factors.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900207-1

Intensive conventional insulin therapy for type II diabetes. Metabolic effects during a 6-mo outpatient trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900207-1

Efficacy and metabolic effects of metformin and troglitazone in type II diabetes mellitus.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900207-1

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900207-1

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900207-1

Effects of troglitazone and metformin on glucose and lipid metabolism: alterations of two distinct molecular pathways

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900207-1

Metabolic effects of new oral hypoglycemic agent CS-045 in NIDDM subjects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900207-1

Troglitazone decreases the proportion of small, dense LDL and increases the resistance of LDL to oxidation in obese subjects.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900207-1

Association of small low-density lipoprotein particles with the incidence of coronary artery disease in men and women.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900207-1

Effects of troglitazone on in vitro oxidation of LDL and HDL induced by copper ions and endothelial cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900207-1

Troglitazone has a scavenging effect on reactive oxygen species

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900207-1

Inhibition of oxidation of low density lipoprotein by troglitazone

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900207-1

Enhancement of insulin sensitivity by troglitazone lowers blood pressure in diabetic hypertensives.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900207-1

Cardiac and glycemic benefits of troglitazone treatment in NIDDM. The Troglitazone Study Group.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900207-1

Effect of troglitazone on fibrinolysis and activated coagulation in patients with non-insulin-dependent diabetes mellitus.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900207-1

Mechanism of metformin action in obese and lean noninsulin-dependent diabetic subjects.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900207-1

Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. The Multicenter Metformin Study Group.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900207-1

Effects of metformin on insulin resistance, risk factors for cardiovascular disease, and plasminogen activator inhibitor in NIDDM subjects. A study of two ethnic groups.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900207-1

Improvement in glucose tolerance and insulin resistance in obese subjects treated with troglitazone

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900207-1

Impaired glucose tolerance is normalized by treatment with the thiazolidinedione troglitazone.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900207-1

Metformin normalizes nonoxidative glucose metabolism in insulin-resistant normoglycemic first-degree relatives of patients with NIDDM

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900207-1

Metformin improves blood lipid pattern in nondiabetic patients with coronary heart disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900207-1

Treating insulin resistance in hypertension with metformin reduces both blood pressure and metabolic risk factors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900207-1

The effect of metformin on blood pressure and metabolism in nondiabetic hypertensive patients.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900207-1

10.1016/S0002-9343(98)00207-1

7 January 2021

Identifiers

DOI

1 reference

release_j2ef3kpbirc2vd2jghoo3o5c2m

28 November 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/j2ef3kpbirc2vd2jghoo3o5c2m

mapped directly with Wikidata item

24 November 2022

based on heuristic

PubMed ID

9707264

1 reference

PubMed ID

9707264